A mathematical model for evaluating the impact of vaccination schedules: Application to Neisseria meningitidis

Epidemiology and Infection

Volumn 130, Issue 3, 2003, Pages 419-429

  Tuckwell, H C ^a   Hanslik, T ^a,b   Valleron, A J ^c   Flahault, A ^a  

^a INSERM   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE;

ACTIVE IMMUNIZATION; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MENINGOCOCCOSIS; MORTALITY; NEISSERIA MENINGITIDIS; SEROTYPE; STATISTICAL CONCEPTS; TREATMENT OUTCOME; VACCINATION;

EID: 0038342033     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0950268803008501     Document Type: Article

References (24)

1. Kaplan EH, Craft DL, Wein LM. Emergency response to a smallpox attack: the case for mass vaccination. Proc Natl Acad Sci USA 2002; 99: 10935-42.
2. Kermack WO, McKendrick AG. Contributions to the mathematical theory of epidemics I. Proc Roy Soc Lond A 1927; 11: 700-21.
3. Bailey NTJ. The mathematical theory of infectious diseases and its application. London: Griffin, 1975.
4. Coen PG, Heath PT, Barbour ML, Garnett GP. Mathematical models of Haemophilus influenzae type b. Epidemiol Infect 1998; 120: 281-95.
5. Hethcote HW. The mathematics of infectious diseases. SIAM Review 2000; 42: 599-653.
6. Leslie PH. On the use of matrices in certain population mathematics. Biometrika 1945; 33: 183-212.
7. Pollard JH. Mathematical models for the growth of human populations. Cambridge: CUP, 1973.
8. Lingappa JR, Rosenstein N, Zell ER, Shutt KA, Schuchat A, Perkins BA. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States. Vaccine 2001; 29: 4566-75.
9. Jodar L, Feavers IM, Salisbury D, Granoff DM. Development of vaccines against meningococcal disease. Lancet 2002; 359: 1499-508.
10. du Chatelet IP, Gessner BD, da Silva A. Comparison of cost-effectiveness of preventive and reactive mass immunization campaigns against meningococcal meningitis in West Africa: a theoretical modelling analysis. Vaccine 2001; 19: 3420-31.
11. Bos JM, Rumke HC, Welte R, Postma MJ, Jager JC. Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program. Vaccine 2002; 20: 202-07.
12. De Wals P, Erickson L. Economic analysis of the 1992-1993 mass immunization campaign against serogroup C meningococcal disease in Quebec. Vaccine 2002; 20: 2840-4.
13. Trotter CL, Edmunds WJ. Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. BMJ 2002; 324: 809-12.
14. Scott RD, Meltzer MI, Erickson LJ, De Wals P, Rosenstein NE. Vaccinating first-year college students living in dormitories for meningococcal disease. An economic analysis. Am J Prev Med 2002; 23: 98-105.
15. Troncoso G, Sanchez S, Criado MT, Ferreiros CM. Analysis of Neisseria lactamica antigens putatively implicated in acquisition of natural immunity to Neisseria meningitidis. FEMS Immunol Med Microbiol 2002; 1417: 1-7.
16. Morley SL, Pollard AJ. Vaccine prevention of meningococcal disease, coming soon? Vaccine 2001; 20: 666-87.
17. Poolman J, Berthet F-X. Alternative vaccine strategies to prevent serogroup B meningococcal diseases. Vaccine 2002; 20: S24-6.
18. Coen PG, Cartwright K, Stuart J. Mathematical modelling of infection and disease due to Neisseria meningitidis and Neisseria lactamica. Int J Epidemiol 2000; 29: 180-8.
19. Benenson AS, ed. Control of communicable diseases manual. Washington, DC: APHA, 1995.
20. Neal KR, Nguyen-Van-Tam JS, Jeffrey N, et al. Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study. BMJ 2000; 320: 846-9.
21. Maiden MCJ, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002; 359: 1829-30.
22. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2002; 20: S58-67.
23. Heath PT, Booy R, Azzopardi HJ, et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA 2000; 284: 2334-40.
24. Ramsay ME, Andrews N, Kacsmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001; 357: 195-6.